1. Home
  2. RMCF vs NXTC Comparison

RMCF vs NXTC Comparison

Compare RMCF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

N/A

Current Price

$0.88

Market Cap

14.9M

ML Signal

N/A

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$6.12

Market Cap

17.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
NXTC
Founded
1981
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
17.3M
IPO Year
2024
2019

Fundamental Metrics

Financial Performance
Metric
RMCF
NXTC
Price
$0.88
$6.12
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
53.3K
89.1K
Earning Date
06-16-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
N/A
Revenue
$30,432,352.00
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.55
52 Week High
$2.99
$15.74

Technical Indicators

Market Signals
Indicator
RMCF
NXTC
Relative Strength Index (RSI) 38.24 46.23
Support Level $0.84 $5.60
Resistance Level $1.19 $8.68
Average True Range (ATR) 0.05 0.88
MACD -0.02 -0.23
Stochastic Oscillator 4.31 19.35

Price Performance

Historical Comparison
RMCF
NXTC

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: